Search Results

Texas Children’s Hospital is pleased to announce the new executive leadership structure at the Texas Children’s Heart Center, which has been ranked number one in the nation for pediatric cardiology and heart surgery by U.S. News and World Report for seven consecutive years.

Cincinnati Children’s has begun work on an Applied Gene and Cell Therapy Center, which will enable the health system to increase clinical trials of innovative drugs and biological therapeutics for patients with cancer, blood diseases or genetic disorders.

Children’s Hospital of Philadelphia announced that it has received a significant philanthropic gift from Mitchell L. Morgan, Dr. Hilarie L. Morgan and their family to name its state-of-the-art research facility currently under construction on the South Street bridge next to CHOP’s Roberts Center for Pediatric Research.

Danaher Corporation, a global science and technology innovator, launched a strategic collaboration with Cincinnati Children’s Hospital Medical Center, with the goal of improving patient safety by addressing a leading cause of failure in clinical trials.

A study published Tuesday in The New England Journal of Medicine showed that children between the ages of six and 12 who took liraglutide for just over a year experienced a significant reduction in body mass index compared to placebo.

Ascendis Pharma A/S (Nasdaq: ASND) today announced the oral presentation of data from its Phase 2 ACcomplisH Trial of TransCon CNP (navepegritide) in children aged 2 to 10 years old with achondroplasia by Ravi Savarirayan, M.D., Murdoch Children’s Research Center (Australia), during ICCBH 2024, the International Conference on Children’s Bone Health being held in Salzburg, Austria.

Inozyme Pharma, Inc. announced a data presentation and sponsored symposium at the 11th International Conference on Children’s Bone Health, which is being held June 22-25, 2024, in Salzburg, Austria.

Physicians at City of Hope, one of the largest cancer research and treatment organizations in the United States, in cooperation with the Children’s Oncology Group (COG), have conducted the largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure.

CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, announced that its UCLA research team has created a promising new drug candidate for treating recurrent Ewing sarcoma, a deadly children’s cancer.